LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Kodu・Aktsiate loetelu・Heron Therapeutics Inc

Heron Therapeutics Inc

Suletud

SektorTervishoid

0.87 2.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.83

Max

0.87

Põhinäitajad
By Trading Economics
Sissetulek	-5.2M -8.1M
Müük	-5.9M 35M
Aktsiakasum	-0.04
Kasumimarginaal	-23.367
Töötajad	128
EBITDA	-4M -4.8M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+306.98% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-68M 163M
Eelmine avamishind	-1.48
Eelmine sulgemishind	0.87

Uudiste sentiment

By Acuity

46%

54%

140 / 344 Pingereas Healthcare

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. mai 2026, 16:52 UTC

Uudisväärsed sündmused

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q Rev $1.76B >SQM

26. mai 2026, 23:57 UTC

Tulu

Sociedad Quimica 1Q EPS $1.28 >SQM

26. mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q EPS $11.61 >WEBC

26. mai 2026, 21:54 UTC

Tulu

Webco Industries 3Q Sales $179.6M >WEBC

26. mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26. mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26. mai 2026, 20:58 UTC

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26. mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26. mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26. mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26. mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26. mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26. mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26. mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26. mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26. mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26. mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26. mai 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

26. mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26. mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26. mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

306.98% tõus

12 kuu keskmine prognoos

Keskmine 3.5 USD 306.98%

Kõrge 4 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Heron Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

140 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.